Skip to content
2000
image of Advancements in Nanotechnology for Targeted Drug Delivery in Chronic Obstructive Pulmonary Disease

Abstract

Nanotechnology has emerged as a transformative platform in the management of chronic obstructive pulmonary disease (COPD), offering targeted, sustained, and patient-friendly therapeutic solutions. Engineered nanocarriers, including liposomes, solid lipid nanoparticles, dendrimers, nanoemulsions, and polymeric nanoparticles enable the precise delivery of bronchodilators, anti-inflammatory agents, gene therapies, and prodrugs directly to inflamed lung tissues. Surface modification with PEG or targeting ligands enhances mucus penetration, circulation time, and receptor-specific uptake while minimizing systemic exposure. Prodrug-loaded nanoparticles remain stable during inhalation and undergo site-specific activation in the diseased pulmonary environment, improving therapeutic efficacy and reducing off-target effects. Furthermore, regenerative medicine approaches, including nanoparticle-assisted stem cell delivery, have shown promise in promoting lung tissue repair and immunomodulation. In addition, an antioxidant nanoparticles, such as gold, cerium oxide, and zinc-based systems, effectively scavenge reactive oxygen species and reduce inflammation, addressing a key pathogenic mechanism in COPD. studies demonstrate improved lung function, reduced cytokine levels, and enhanced bioavailability using these nano-based strategies. Collectively, these advancements signify a paradigm shift in COPD treatment from broad symptom relief to precision-targeted molecular intervention. With further clinical translation, nanotechnology holds the potential to revolutionize disease management, restoring respiratory function and enhancing quality of life for millions of patients worldwide.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cms/10.2174/0126661454405390251015163802
2025-11-04
2026-02-24

  • From This Site

    /content/journals/cms/10.2174/0126661454405390251015163802
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Safiri S. Carson-Chahhoud K. Noori M. Burden of chronic obstructive pulmonary disease and its attributable risk factors in 204 countries and territories, 1990-2019: Results from the Global Burden of Disease Study 2019. BMJ 2022 378 e069679 10.1136/bmj‑2021‑069679 35896191
    [Google Scholar]
  2. Agustí A. Celli B.R. Criner G.J. Global initiative for chronic obstructive lung disease 2023 report: GOLD executive summary. Am. J. Respir. Crit. Care Med. 2023 207 7 819 837 10.1164/rccm.202301‑0106PP 36856433
    [Google Scholar]
  3. Chronic obstructive pulmonary disease (COPD) 2024 Available from: https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd)
  4. Miravitlles M. Worth H. Soler Cataluña J.J. Observational study to characterise 24-hour COPD symptoms and their relationship with patient-reported outcomes: Results from the ASSESS study. Respir. Res. 2014 15 1 122 10.1186/s12931‑014‑0122‑1 25331383
    [Google Scholar]
  5. Tsiligianni I. Kocks J.W.H. Daytime symptoms of chronic obstructive pulmonary disease: A systematic review. NPJ Prim. Care Respir. Med. 2020 30 1 6 10.1038/s41533‑020‑0163‑5 32081967
    [Google Scholar]
  6. Prasad B. Chronic Obstructive Pulmonary Disease (COPD). Int J Pharm Res Technol 2020 10 1 67 71 10.31838/ijprt/10.01.12
    [Google Scholar]
  7. Koch A. Weiser T. Update on COPD management: Current treatments and future directions. Respir. Med. 2023 206 106067 10.1016/j.rmed.2023.106067
    [Google Scholar]
  8. Rabe K.F. Rennard S. Martinez F.J. Targeting type 2 inflammation and epithelial alarmins in chronic obstructive pulmonary disease: A biologics outlook. Am. J. Respir. Crit. Care Med. 2023 208 4 395 405 10.1164/rccm.202303‑0455CI 37348121
    [Google Scholar]
  9. Calverley P.M.A. Walker P. Management of chronic obstructive pulmonary disease: A review of current guidelines. Chest 2022 162 4 971 983 10.1016/j.chest.2022.06.007 34592317
    [Google Scholar]
  10. Hanania N.A. Ambrosino N. Calverley P. Treatments for COPD. Respir. Med. 2005 99 Suppl. 2 S28 S40 10.1016/j.rmed.2005.09.013
    [Google Scholar]
  11. Barnes P.J. New treatments for copd. Nat. Rev. Drug Discov. 2002 1 6 437 446 10.1038/nrd820 12119745
    [Google Scholar]
  12. Verbeek P.R. Grit M. Side effects and cardiovascular risks of long-term bronchodilator use in chronic obstructive pulmonary disease. J. Clin. Med. 2023 12 5 1653 10.3390/jcm12051653
    [Google Scholar]
  13. Criner G. Marchetti N. Surgical approaches to treating emphysema: Lung volume reduction surgery, bullectomy, and lung transplantation. Semin. Respir. Crit. Care Med. 2015 36 4 592 608 10.1055/s‑0035‑1556064 26238644
    [Google Scholar]
  14. Nashef S.A.M. Badr A. Surgical interventions in chronic obstructive pulmonary disease: Risks and outcomes. Thorac. Surg. Clin. 2023 33 1 109 120 10.1016/j.thorsurg.2022.09.003 36372527
    [Google Scholar]
  15. Nsairat H. Khater D. Sayed U. Odeh F. Al Bawab A. Alshaer W. Liposomes: Structure, composition, types, and clinical applications. Heliyon 2022 8 5 e09394 10.1016/j.heliyon.2022.e09394 35600452
    [Google Scholar]
  16. Sharma R. Kumar V. Nano enabled agriculture for sustainable soil. Waste Manag BulL 2024 2 1 152 161 10.1016/j.wmb.2024.01.002
    [Google Scholar]
  17. Nzilu D.M. Madivoli E.S. Makhanu D. Environmental remediation using nanomaterial as adsorbents for emerging micropollutants. Environ. Nanotechnol. Monit. Manag. 2023 20 100789 10.1016/j.enmm.2023.100789
    [Google Scholar]
  18. Heo J. Reid T. Ruo L. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat. Med. 2013 19 3 329 336 10.1038/nm.3089 23396206
    [Google Scholar]
  19. Sultana S. Talegaonkar S. Nishad D.K. Mittal G. Ahmad F.J. Bhatnagar A. Alpha ketoglutarate nanoparticles: A potentially effective treatment for cyanide poisoning. Eur. J. Pharm. Biopharm. 2018 126 221 232 10.1016/j.ejpb.2017.06.017 28629719
    [Google Scholar]
  20. Zhang Y. Zhang J. Preparation of budesonide nanosuspensions for pulmonary delivery: Characterization, in vitro release and in vivo lung distribution studies. Artif. Cells Nanomed. Biotechnol. 2016 44 1 285 289 10.3109/21691401.2014.944645 25100657
    [Google Scholar]
  21. Chishti N. Jagwani S. Dhamecha D. Jalalpure S. Dehghan M.H. Preparation, optimization, and in vivo evaluation of nanoparticle-based formulation for pulmonary delivery of anticancer drug. Medicina 2019 55 6 294 10.3390/medicina55060294 31226865
    [Google Scholar]
  22. Wu J. Deng C. Meng F. Zhang J. Sun H. Zhong Z. Hyaluronic acid coated PLGA nanoparticulate docetaxel effectively targets and suppresses orthotopic human lung cancer. J. Control. Release 2017 259 76 82 10.1016/j.jconrel.2016.12.024 28027947
    [Google Scholar]
  23. Varshosaz J. Hassanzadeh F. Mardani A. Rostami M. Feasibility of haloperidol-anchored albumin nanoparticles loaded with doxorubicin as dry powder inhaler for] pulmonary delivery. Pharm. Dev. Technol. 2015 20 2 183 196 10.3109/10837450.2013.852576 24219091
    [Google Scholar]
  24. Ferguson L.T. Ma X. Myerson J.W. Mechanisms] by which liposomes improve inhaled drug delivery for] alveolar diseases. Adv. NanoBiomed Res. 2023 3 3 2200106 10.1002/anbr.202200106 37266328
    [Google Scholar]
  25. Chennakesavulu S. Mishra A. Sudheer A. Sowmya C. Suryaprakash Reddy C. Bhargav E. Pulmonary delivery of liposomal dry powder inhaler formulation for effective treatment of idiopathic pulmonary fibrosis. Asian J. Pharm. Sci. 2018 13 1 91 100 10.1016/j.ajps.2017.08.005 32104382
    [Google Scholar]
  26. Sangkana S. Eawsakul K. Ongtanasup T. Preparation and evaluation of a niosomal delivery system containing G. mangostana extract and study of its anti- Acanthamoeba activity. Nanoscale Adv. 2024 6 5 1467 1479 10.1039/D3NA01016C 38419876
    [Google Scholar]
  27. Zaid Alkilani A. Hamed R. Abdo H. Formulation and evaluation of azithromycin-loaded niosomal gel: Optimization, in vitro studies, rheological characterization, and cytotoxicity study. ACS Omega 2022 7 44 39782 39793 10.1021/acsomega.2c03762 36385887
    [Google Scholar]
  28. Duong VA Nguyen TTL Maeng HJ Preparation of solid lipid nanoparticles and nanostructured lipid carriers for drug delivery and the effects of preparation parameters of solvent injection method. Molecules 2020 25 20 10.3390/molecules25204781 33081021
  29. Gajbhiye K.R. Pawar A. Mahadik K.R. Gajbhiye V. PEGylated nanocarriers: A promising tool for targeted delivery to the brain. Colloids Surf. B Biointerfaces 2020 187 110770 10.1016/j.colsurfb.2019.110770 31926790
    [Google Scholar]
  30. Sehgal S. Kumar J. Nishtha. Involvement of gold and silver nanoparticles in lung cancer nanomedicines: A review. Mater. Today Proc. 2022 62 Part 12 6468 6476 10.1016/j.matpr.2022.04.199
    [Google Scholar]
  31. Dhamecha D. Jalalpure S. Jadhav K. Doxorubicin functionalized gold nanoparticles: Characterization and activity against human cancer cell lines. Process Biochem. 2015 50 12 2298 2306 10.1016/j.procbio.2015.10.007
    [Google Scholar]
  32. Leong E.W.X. Ge R. Lipid nanoparticles as delivery vehicles for inhaled therapeutics. Biomedicines 2022 10 9 2179 10.3390/biomedicines10092179 36140280
    [Google Scholar]
  33. Samaridou E. Heyes J. Lutwyche P. Lipid nanoparticles for nucleic acid delivery: Current perspectives. Adv. Drug Deliv. Rev. 2020 154-155 37 63 10.1016/j.addr.2020.06.002 32526452
    [Google Scholar]
  34. Shu L. Wang W. Ng C. A pilot study exploiting] the industrialization potential of solid lipid nanoparticle-based metered-dose inhalers. Pharmaceutics 2023 15 3 866 10.3390/pharmaceutics15030866 36986727
    [Google Scholar]
  35. Pandey S. Shaikh F. Gupta A. Tripathi P. Yadav J.S. A recent update: Solid lipid nanoparticles for effective drug delivery. Adv. Pharm. Bull. 2022 12 1 17 33 [PMID: 35517874
    [Google Scholar]
  36. Li N. Li X. Cheng P. Preparation of curcumin solid lipid nanoparticles loaded with flower-shaped lactose for lung inhalation and preliminary evaluation of cytotoxicity in vitro. Evid. Based Complement. Alternat. Med. 2021 2021 1 15 10.1155/2021/4828169 34745284
    [Google Scholar]
  37. Peng J. Cai Z. Wang Q. Carboxymethyl chitosan modified oxymatrine liposomes for the alleviation of emphysema in mice via pulmonary administration. Molecules 2022 27 11 3610 10.3390/molecules27113610 35684546
    [Google Scholar]
  38. Kaur G. Narang R.K. Rath G. Goyal A.K. Advances in pulmonary delivery of nanoparticles. Artif. Cells Blood Substit. Immobil. Biotechnol. 2012 40 1-2 75 96 10.3109/10731199.2011.592494 21806501
    [Google Scholar]
  39. Iyer R. Hsia C. Nguyen K. Nano-therapeutics for the lung: State-of-the-art and future perspectives. Curr. Pharm. Des. 2015 21 36 5233 5244 10.2174/1381612821666150923095742 26412358
    [Google Scholar]
  40. Esmaeili M. Aghajani M. Abbasalipourkabir R. Amani A. Budesonide-loaded solid lipid nanoparticles for pulmonary delivery: preparation, optimization, and aerodynamic behavior. Artif. Cells Nanomed. Biotechnol. 2016 44 8 1964 1971 10.3109/21691401.2015.1129614 26758698
    [Google Scholar]
  41. Gaspar D.P. Gaspar M.M. Eleutério C.V. Microencapsulated solid lipid nanoparticles as a hybrid platform for pulmonary antibiotic delivery. Mol. Pharm. 2017 14 9 2977 2990 10.1021/acs.molpharmaceut.7b00169 28809501
    [Google Scholar]
  42. Jha S Sharma PK Malviya R Liposomal drug delivery system for cancer therapy: advancement and patents. Recent Pat Drug Deliv Formul 2016 10 3 177 83 10.2174/1872211310666161004155757 27712569
  43. van der Koog L. Gandek T.B. Nagelkerke A. Liposomes and extracellular vesicles as drug delivery systems: A comparison of composition, pharmacokinetics, and functionalization. Adv. Healthc. Mater. 2022 11 5 2100639 10.1002/adhm.202100639 34165909
    [Google Scholar]
  44. Chen T Gong T Zhao T Fu Y Zhang Z Gong T. A A comparison study between lycobetaine-loaded nanoemulsion and liposome using nRGD as therapeutic adjuvant for lung cancer therapy. Eur J Pharm Sci 2018 111 293 302 10.1016/j.ejps.2017.09.041 28966099
    [Google Scholar]
  45. Fathi S. Oyelere A.K. Liposomal drug delivery systems for targeted cancer therapy: Is active targeting the best choice? Future Med. Chem. 2016 8 17 2091 2112 10.4155/fmc‑2016‑0135 27774793
    [Google Scholar]
  46. Huang Y. Zhang J. Wang X. Jing H. Li H. Aerosol inhalation of gene delivery therapy for pulmonary diseases. Biomolecules 2024 14 8 904 10.3390/biom14080904 39199292
    [Google Scholar]
  47. Fulton M.D. Najahi-Missaoui W. Liposomes in cancer therapy: How did we start and where are we now. Int. J. Mol. Sci. 2023 24 7 6615 10.3390/ijms24076615 37047585
    [Google Scholar]
  48. Forte J. Hanieh P.N. Poerio N. Mucoadhesive rifampicin-liposomes for the treatment of pulmonary infection by Mycobacterium abscessus: Chitosan or ε-poly-L-lysine decoration. Biomolecules 2023 13 6 924 10.3390/biom13060924 37371504
    [Google Scholar]
  49. Bassetti M. Vena A. Russo A. Peghin M. Inhaled liposomal antimicrobial delivery in lung infections. Drugs 2020 80 13 1309 1318 10.1007/s40265‑020‑01359‑z 32691293
    [Google Scholar]
  50. Liu J. Platinum nanoparticles: Antioxidant mechanisms and applications in respiratory diseases. Int. J. Nanomedicine 2022 17 3421 3432 10.2147/IJN.S340067
    [Google Scholar]
  51. Arber Raviv S. Alyan M. Egorov E. Lung targeted liposomes for treating ARDS. J. Control. Release 2022 346 421 433 10.1016/j.jconrel.2022.03.028 35358610
    [Google Scholar]
  52. Shaikh M.A.J. Goyal K. Afzal M. Liposome-encapsulated therapies: Precision medicine for inflammatory lung disorders. Nano TransMed 2025 4 100082 10.1016/j.ntm.2025.100082
    [Google Scholar]
  53. Kotta S. Aldawsari H.M. Badr-Eldin S.M. Aerosol delivery of surfactant liposomes for management of pulmonary fibrosis: An approach supporting pulmonary mechanics. Pharmaceutics 2021 13 11 1851 10.3390/pharmaceutics13111851 34834265
    [Google Scholar]
  54. De Leo V. Ruscigno S. Trapani A. Preparation of drug-loaded small unilamellar liposomes and evaluation of their potential for the treatment of chronic respiratory diseases. Int. J. Pharm. 2018 545 1-2 378 388 10.1016/j.ijpharm.2018.04.030 29678545
    [Google Scholar]
  55. Sharifi-Rad J. Rayess Y.E. Rizk A.A. Turmeric and its major compound curcumin on health: Bioactive effects and safety profiles for food, pharmaceutical, biotechnological and medicinal applications. Front. Pharmacol. 2020 11 01021 10.3389/fphar.2020.01021 33041781
    [Google Scholar]
  56. Mohari S.B.M. Taylor K.M.G. Nimmano N. Preparation and characterization of curcumin-loaded liposomes for delivery to the lungs. Thai J Pharm Sci 2022 46 3 293 299 10.56808/3027‑7922.2573
    [Google Scholar]
  57. Lukhele B.S. Bassey K. Witika B.A. The utilization of plant-material-loaded vesicular drug delivery systems in the management of pulmonary diseases. Curr. Issues Mol. Biol. 2023 45 12 9985 10017 10.3390/cimb45120624 38132470
    [Google Scholar]
  58. Saxena J. Bisen M. Misra A. Targeting COPD with PLGA‐based nanoparticles: Current status and prospects. BioMed Res. Int. 2022 2022 1 5058121 10.1155/2022/5058121 35309178
    [Google Scholar]
  59. Gupta P. Singh A. Verma A. The anti-tumor and immunomodulatory effects of PLGA-based docetaxel nanoparticles in lung cancer: The potential involvement of necroptotic cell death through reactive oxygen species and calcium build-up. Vaccines 2022 10 11 1801 10.3390/vaccines10111801 36366309
    [Google Scholar]
  60. Patel P. Raval M. Manvar A. Airao V. Bhatt V. Shah P. Lung cancer targeting efficiency of silibinin loaded poly caprolactone/pluronic F68 inhalable nanoparticles: In vitro and in vivo study. PLoS One 2022 17 5 e0267257 10.1371/journal.pone.0267257 35560136
    [Google Scholar]
  61. Mohammed S.W. El-Megrab N.A. Hasan A.A. Gomaa E. A remodeled ivermectin polycaprolactone-based nanoparticles for inhalation as a promising treatment of pulmonary inflammatory diseases. Eur. J. Pharm. Sci. 2024 195 106714 10.1016/j.ejps.2024.106714 38301972
    [Google Scholar]
  62. Yordanov G. Evangelatov A. Skrobanska R. Epirubicin loaded to pre-polymerized poly(butyl cyanoacrylate) nanoparticles: Preparation and in vitro evaluation in human lung adenocarcinoma cells. Colloids Surf. B Biointerfaces 2013 107 115 123 10.1016/j.colsurfb.2013.02.002 23466549
    [Google Scholar]
  63. Hu X. Yang F. Liao Y. Li L. Zhao G. Zhang L. Docetaxel-loaded cholesterol-PEG co-modified poly (n-Butyl) cyanoacrylate nanoparticles for antitumor drug pulmonary delivery: Preparation, characterization, and in vivo evaluation. Int. J. Nanomedicine 2020 15 5361 5376 10.2147/IJN.S249511 32801694
    [Google Scholar]
  64. Tseng C. Wang T. Dong G. Development of gelatin nanoparticles with biotinylated EGF conjugation for lung cancer targeting. Biomaterials 2007 28 27 3996 4005 10.1016/j.biomaterials.2007.05.006 17570484
    [Google Scholar]
  65. Abdelrady H. Hathout R.M. Osman R. Saleem I. Mortada N.D. Exploiting gelatin nanocarriers in the pulmonary delivery of methotrexate for lung cancer therapy. Eur. J. Pharm. Sci. 2019 133 115 126 10.1016/j.ejps.2019.03.016 30905615
    [Google Scholar]
  66. Kazmi I. Shaikh M.A.J. Afzal O. Chitosan-based nano drug delivery system for lung cancer. J. Drug Deliv. Sci. Technol. 2023 81 March 104196 10.1016/j.jddst.2023.104196
    [Google Scholar]
  67. Vikas Mehata AK Viswanadh MK EGFR targeted redox sensitive chitosan nanoparticles of cabazitaxel: Dual targeted cancer therapy, lung distribution, and targeting studies by photoacoustic and optical imaging. Biomacro molecules 2023 24 11 4989 5003 10.1021/acs.biomac.3c00658 37871263
  68. Ullah F. Shah K.U. Shah S.U. Synthesis, characterization and in vitro evaluation of chitosan nanoparticles physically admixed with lactose microspheres for pulmonary delivery of montelukast. Polymers 2022 14 17 3564 10.3390/polym14173564 36080637
    [Google Scholar]
  69. Elmowafy M. Shalaby K. Elkomy M.H. Polymeric nanoparticles for delivery of natural bioactive agents: Recent advances and challenges. Polymers 2023 15 5 1123 10.3390/polym15051123 36904364
    [Google Scholar]
  70. Begines B. Ortiz T. Pérez-Aranda M. Polymeric nanoparticles for drug delivery: Recent developments and future prospects. Nanomaterials 2020 10 7 1403 10.3390/nano10071403 32707641
    [Google Scholar]
  71. Paranjpe M. Müller-Goymann C. Nanoparticle-mediated pulmonary drug delivery: A review. Int. J. Mol. Sci. 2014 15 4 5852 5873 10.3390/ijms15045852 24717409
    [Google Scholar]
  72. Lim Y.H. Tiemann K.M. Hunstad D.A. Elsabahy M. Wooley K.L. Polymeric nanoparticles in development for treatment of pulmonary infectious diseases. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2016 8 6 842 871 10.1002/wnan.1401 27016134
    [Google Scholar]
  73. Elsayed N. Stimuli-responsive nanoparticles for lung disorder treatment: From serendipity to precision phosphorylation modulation and drug repurposing. Next Nanotechnology 2025 7 100182 10.1016/j.nxnano.2025.100182
    [Google Scholar]
  74. Peng L. Liu S. Feng A. Yuan J. Polymeric nanocarriers based on cyclodextrins for drug delivery: Host–guest interaction as stimuli responsive linker. Mol. Pharm. 2017 14 8 2475 2486 10.1021/acs.molpharmaceut.7b00160 28463008
    [Google Scholar]
  75. Mohamed A. Kunda N. Ross K. Hutcheon G.A. Polymeric nanoparticles for the delivery of miRNA to treat Chronic Obstructive Pulmonary Disease (COPD). Eur. J. Pharm. Biopharm. 2017 2019 136 [PMID: 30615927
    [Google Scholar]
  76. Craparo E.F. Cabibbo M. Scialabba C. Giammona G. Cavallaro G. Inhalable formulation based on lipid–polymer hybrid nanoparticles for the macrophage targeted delivery of roflumilast. Biomacromolecules 2022 23 8 3439 3451 10.1021/acs.biomac.2c00576 35899612
    [Google Scholar]
  77. Dahmash E.Z. Achkar N.R. Ali D.K. Preclinical evaluation of novel synthesised nanoparticles based on tyrosine poly(ester amide) for improved targeted pulmonary delivery. Sci. Rep. 2024 14 1 9845 10.1038/s41598‑024‑59588‑1 38684750
    [Google Scholar]
  78. Buhecha M.D. Lansley A.B. Somavarapu S. Pannala A.S. Development and characterization of PLA nanoparticles for pulmonary drug delivery: Co-encapsulation of theophylline and budesonide, a hydrophilic and lipophilic drug. J. Drug Deliv. Sci. Technol. 2019 53 October 101128 10.1016/j.jddst.2019.101128
    [Google Scholar]
  79. Kolte A. Patil S. Lesimple P. Hanrahan J.W. Misra A. PEGylated composite nanoparticles of PLGA and polyethylenimine for safe and efficient delivery of pDNA to lungs. Int. J. Pharm. 2017 524 1-2 382 396 10.1016/j.ijpharm.2017.03.094 28391040
    [Google Scholar]
  80. Guo X. Zuo X. Zhou Z. PLGA-based micro/nanoparticles: An overview of their applications in respiratory diseases. Int. J. Mol. Sci. 2023 24 5 4333 10.3390/ijms24054333 36901762
    [Google Scholar]
  81. Acharya S. Guru B.R. Prednisolone encapsulated PLGA nanoparticles: Characterization, cytotoxicity, and anti-inflammatory activity on C6 glial cells. J. Appl. Pharm. Sci. 2020 10 4 14 21 10.7324/JAPS.2020.104003
    [Google Scholar]
  82. Alshetaili A.S. Gefitinib loaded PLGA and chitosan coated PLGA nanoparticles with magnified cytotoxicity against A549 lung cancer cell lines. Saudi J. Biol. Sci. 2021 28 9 5065 5073 10.1016/j.sjbs.2021.05.025 34466084
    [Google Scholar]
  83. Al-Nemrawi N. Alshraiedeh N.A. Zayed A. Altaani B. Low molecular weight chitosan-coated plga nanoparticles for pulmonary delivery of tobramycin for cystic fibrosis. Pharmaceuticals 2018 11 1 28 10.3390/ph11010028 29517998
    [Google Scholar]
  84. Babu A. Amreddy N. Muralidharan R. Chemodrug delivery using integrin-targeted PLGA-Chitosan nanoparticle for lung cancer therapy. Sci. Rep. 2017 7 1 14674 10.1038/s41598‑017‑15012‑5 29116098
    [Google Scholar]
  85. Gomes dos Reis L. Lee W.H. Svolos M. Delivery of pDNA to lung epithelial cells using PLGA nanoparticles formulated with a cell-penetrating peptide: understanding the intracellular fate. Drug Dev. Ind. Pharm. 2020 46 3 427 442 10.1080/03639045.2020.1724134 32070151
    [Google Scholar]
  86. Piperno A. Sciortino M.T. Giusto E. Montesi M. Recent advances and challenges in gene delivery mediated by polyester-based nanoparticles. Int. J. Nanomedicine 2021 16 5981 6002 10.2147/IJN.S321329
    [Google Scholar]
  87. Amreddy N. Babu A. Muralidharan R. Munshi A. Ramesh R. Polymeric nanoparticle-mediated gene delivery for lung cancer treatment. Top. Curr. Chem. 2017 375 2 35 10.1007/s41061‑017‑0128‑5 28290155
    [Google Scholar]
  88. Machado G.T.P. Veleirinho M.B. Honorato L.A. Kuhnen S. Formulation and evaluation of anti-MRSA nanoemulsion loaded with Achyroclinesatureioides: A new sustainable strategy for the bovine mastitis. Nano Ex 2020 1 030004 10.1088/2632‑959X/abbcac
    [Google Scholar]
  89. George M. Boukherroub R. Sanyal A. Szunerits S. Treatment of lung diseases via nanoparticles and nanorobots: Are these viable alternatives to overcome current treatments? Mater. Today Bio 2025 31 101616 10.1016/j.mtbio.2025.101616 40124344
    [Google Scholar]
  90. Kim J.E. Park Y.J. Improved antitumor efficacy of hyaluronic acid-complexed paclitaxel nanoemulsions in treating non-small cell lung cancer. Biomol. Ther. 2017 25 4 411 416 10.4062/biomolther.2016.261 28208014
    [Google Scholar]
  91. Amani A. York P. Chrystyn H. Clark B.J. Evaluation of a nanoemulsion-based formulation for respiratory delivery of budesonide by nebulizers. AAPS PharmSciTech 2010 11 3 1147 1151 10.1208/s12249‑010‑9486‑9 20652776
    [Google Scholar]
  92. Tulbah A.S. Bader A. Ong H.X. Traini D. In vitro evaluation of nebulized eucalyptol nano-emulsion formulation as a potential COVID-19 treatment. Saudi Pharm. J. 2022 30 12 1691 1699 10.1016/j.jsps.2022.09.014 36164456
    [Google Scholar]
  93. Jawaid T. Alaseem A.M. Khan M.M. Preparation and evaluation of nanoemulsion of citronella essential oil with improved antimicrobial and anti-cancer properties. Antibiotics 2023 12 3 478 10.3390/antibiotics12030478 36978345
    [Google Scholar]
  94. Dosoky N.S. Setzer W.N. Biological activities and safety of Citrus spp. essential oils. Int. J. Mol. Sci. 2018 19 7 1966 10.3390/ijms19071966
    [Google Scholar]
  95. Manaa A.O. Baghdadi H.H. El-Nikhely N.A. Heikal L.A. El-Hosseiny L.S. Oregano oil-nanoemulsions: Formulation and evaluation of antibacterial and anticancer potentials. J. Drug Deliv. Sci. Technol. 2022 78 December 103978 10.1016/j.jddst.2022.103978
    [Google Scholar]
  96. Nirmala M.J. Durai L. Gopakumar V. Nagarajan R. Preparation of celery essential oil-based nanoemulsion by ultrasonication and evaluation of its potential anticancer and antibacterial activity. Int. J. Nanomedicine 2020 15 7651 7666 10.2147/IJN.S252640 33116493
    [Google Scholar]
  97. De Rubis G. Paudel K.R. Manandhar B. Agarwood oil nanoemulsion attenuates cigarette smoke-induced inflammation and oxidative stress markers in BCi-NS1.1 airway epithelial cells. Nutrients 2023 15 4 1019 10.3390/nu15041019 36839377
    [Google Scholar]
  98. Sharma A.D. Farmaha M. Kaur I. Preparation and characterization of O/W nanoemulsion with eucalyptus essential oil and study of in vitro antibacterial activity. Nanomed Res J 2020 5 4 347 254 10.22034/nmrj.2020.04.006
    [Google Scholar]
  99. Zhang N. Bian Y. Yao L. Essential oils of Gardenia jasminoides J. Ellis and Gardenia jasminoides f. longicarpa Z.W. Xie & M. Okada flowers: Chemical characterization and assessment of anti-inflammatory effects in alveolar macrophage. Pharmaceutics 2022 14 5 966 10.3390/pharmaceutics14050966 35631552
    [Google Scholar]
  100. Al ayoub Y Gopalan RC Najafzadeh M Development and evaluation of nanoemulsion and microsuspension formulations of curcuminoids for lung delivery with a novel approach to understanding the aerosol performance of nanoparticles Int J Pharm 2019 557 254 63 10.1016/j.ijpharm.2018.12.042 30597263
    [Google Scholar]
  101. Bharatwaj B. Mohammad A.K. Dimovski R. Dendrimer nanocarriers for transport modulation across models of the pulmonary epithelium. Mol. Pharm. 2015 12 3 826 838 10.1021/mp500662z 25455560
    [Google Scholar]
  102. Bober Z. Bartusik-Aebisher D. Aebisher D. Application of dendrimers in anticancer diagnostics and therapy. Molecules 2022 27 10 3237 10.3390/molecules27103237 35630713
    [Google Scholar]
  103. Wang J. Li B. Qiu L. Qiao X. Yang H. Dendrimer-based drug delivery systems: History, challenges, and latest developments. J. Biol. Eng. 2022 16 1 18 10.1186/s13036‑022‑00298‑5 35879774
    [Google Scholar]
  104. Luo M.X. Hua S. Shang Q.Y. Application of nanotechnology in drug delivery systems for respiratory diseases.(Review) Mol. Med. Rep. 2021 23 5 325 10.3892/mmr.2021.11964 33760125
    [Google Scholar]
  105. Gaitsch H. Hersh A.M. Alomari S. Tyler B.M. Dendrimer technology in glioma: Functional design and potential applications. Cancers 2023 15 4 1075 10.3390/cancers15041075 36831418
    [Google Scholar]
  106. Zhang W. Wang Y. Kan X. Wang X. Geng D. Preparation and evaluation of peptide-dendrimer-paclitaxel conjugates for treatment of heterogeneous stage 1 nonsmall cell lung cancer in 293T and L132 cell lines. Trop. J. Pharm. Res. 2017 16 4 737 742 10.4314/tjpr.v16i4.1
    [Google Scholar]
  107. Ryan G.M. Kaminskas L.M. Kelly B.D. Owen D.J. McIntosh M.P. Porter C.J.H. Pulmonary administration of PEGylated polylysine dendrimers: Absorption from the lung versus retention within the lung is highly size-dependent. Mol. Pharm. 2013 10 8 2986 2995 10.1021/mp400091n 23750747
    [Google Scholar]
  108. Nasr M. Najlah M. D’Emanuele A. Elhissi A. PAMAM dendrimers as aerosol drug nanocarriers for pulmonary delivery via nebulization. Int. J. Pharm. 2014 461 1-2 242 250 10.1016/j.ijpharm.2013.11.023 24275446
    [Google Scholar]
  109. Lu P. Leslie F. Wang H. Discovery, validation, and prodrug design of an ACE2 activator for treating bacterial infection-induced lung inflammation. J. Control. Release 2023 364 1 11 10.1016/j.jconrel.2023.10.025 37858626
    [Google Scholar]
  110. Unnikrishnan G. Joy A. Megha M. Kolanthai E. Senthilkumar M. Exploration of inorganic nanoparticles for revolutionary drug delivery applications: A critical review. Discov. Nano 2023 18 1 157 10.1186/s11671‑023‑03943‑0 38112849
    [Google Scholar]
  111. García-Fernández A. Sancenón F. Martínez-Máñez R. Mesoporous silica nanoparticles for pulmonary drug delivery. Adv. Drug Deliv. Rev. 2021 177 October 113953 10.1016/j.addr.2021.113953 34474094
    [Google Scholar]
  112. Hood E.D. Chorny M. Greineder C.F.S. S Alferiev I, Levy RJ, Muzykantov VR. Endothelial targeting of nanocarriers loaded with antioxidant enzymes for protection against vascular oxidative stress and inflammation. Biomaterials 2014 35 11 3708 3715 10.1016/j.biomaterials.2014.01.023 24480537
    [Google Scholar]
  113. Altammar K.A. A review on nanoparticles: Characteristics, synthesis, applications, and challenges. Front. Microbiol. 2023 14 1155622 10.3389/fmicb.2023.1155622 37180257
    [Google Scholar]
  114. Mehrabi Nasab D. Taheri A. Athari S.S. Evaluation anti-inflammatory effect of conjugated gold nanoparticles with cortistatin peptide as drug delivery to asthmatic lung tissue. Int. J. Pept. Res. Ther. 2023 29 1 16 10.1007/s10989‑022‑10487‑x
    [Google Scholar]
  115. Geiser M. Quaile O. Wenk A. Cellular uptake and localization of inhaled gold nanoparticles in lungs of mice with chronic obstructive pulmonary disease. Part. Fibre Toxicol. 2013 10 1 19 10.1186/1743‑8977‑10‑19 23680060
    [Google Scholar]
  116. van Rijt S.H. Bölükbas D.A. Argyo C. Applicability of avidin protein coated mesoporous silica nanoparticles as drug carriers in the lung. Nanoscale 2016 8 15 8058 8069 10.1039/C5NR04119H 27021247
    [Google Scholar]
  117. Ferchichi S. Trabelsi H. Azzouz I. Evaluation of oxidative response and tissular damage in rat lungs exposed to silica-coated gold nanoparticles under static magnetic fields. Int. J. Nanomedicine 2016 11 2711 2719 10.2147/IJN.S103140 27354800
    [Google Scholar]
  118. Hozayen W. Mahmoud A. Desouky E. El-Nahass E. Soliman H. Farghali A. Cardiac and pulmonary toxicity of mesoporous silica nanoparticles is associated with excessive ROS production and redox imbalance in Wistar rats. Biomed. Pharmacother. 2019 109 2527 2538 10.1016/j.biopha.2018.11.093
    [Google Scholar]
  119. Ayre J. Redmond J.M. Vitulli G. Design, Synthesis, and Evaluation of Lung-Retentive Prodrugs for Extending the Lung Tissue Retention of Inhaled Drugs. J. Med. Chem. 2022 65 14 9802 9818 10.1021/acs.jmedchem.2c00416 35798565
    [Google Scholar]
  120. Jornada D. Dos Santos Fernandes G. Chiba D. De Melo T. Dos Santos J. Chung M. The prodrug approach: A successful tool for improving drug solubility. Molecules 2015 21 1 42 10.3390/molecules21010042 26729077
    [Google Scholar]
  121. Chen K.J. Plaunt A.J. Leifer F.G. Kang J.Y. Cipolla D. Recent advances in prodrug-based nanoparticle therapeutics. Eur. J. Pharm. Biopharm. 2021 165 219 243 10.1016/j.ejpb.2021.04.025 33979661
    [Google Scholar]
  122. Zhang W. Li C. Shen C. Prodrug-based nano-drug delivery system for co-encapsulate paclitaxel and carboplatin for lung cancer treatment. Drug Deliv. 2016 23 7 2575 2580 10.3109/10717544.2015.1035466 26056720
    [Google Scholar]
  123. Wang M. Li J. Dong S. Silica nanoparticles induce lung inflammation in mice via ROS/PARP/TRPM2 signaling-mediated lysosome impairment and autophagy dysfunction. Part. Fibre Toxicol. 2020 17 1 23 10.1186/s12989‑020‑00353‑3 32513195
    [Google Scholar]
  124. Campa C.C. Silva R.L. Margaria J.P. Inhalation of the prodrug PI3K inhibitor CL27c improves lung function in asthma and fibrosis. Nat. Commun. 2018 9 1 5232 10.1038/s41467‑018‑07698‑6 30542075
    [Google Scholar]
  125. Hu H. Mady Traore M.D. Li R. Optimization of the prodrug moiety of remdesivir to improve lung exposure/selectivity and enhance Anti-SARS-CoV-2 activity. J. Med. Chem. 2022 65 18 12044 12054 10.1021/acs.jmedchem.2c00758 36070561
    [Google Scholar]
  126. Corboz M.R. Zhang J. LaSala D. Therapeutic administration of inhaled INS1009, a treprostinil prodrug formulation, inhibits bleomycin-induced pulmonary fibrosis in rats. Pulm. Pharmacol. Ther. 2018 49 95 103 10.1016/j.pupt.2018.01.012
    [Google Scholar]
  127. Broekman W. Khedoe P.P.S.J. Schepers K. Roelofs H. Stolk J. Hiemstra P.S. Mesenchymal stromal cells: A novel therapy for the treatment of chronic obstructive pulmonary disease? Thorax 2018 73 6 565 574 10.1136/thoraxjnl‑2017‑210672 29653970
    [Google Scholar]
  128. Jin H. Zhao Y. Yao Y. Intratracheal administration of stem cell membrane-cloaked naringin-loaded biomimetic nanoparticles promotes resolution of acute lung injury. Antioxidants 2024 13 3 282 10.3390/antiox13030282 38539816
    [Google Scholar]
  129. Qin A. Chen S. Li S. Artificial stem cells mediated inflammation-tropic delivery of antiviral drugs for pneumonia treatment. J. Nanobiotechnology 2022 20 1 335 10.1186/s12951‑022‑01547‑x 35842662
    [Google Scholar]
  130. Becerra J. Duran I. Inflammation, a common mechanism in frailty and COVID-19, and stem cells as a therapeutic approach. Stem Cells Transl. Med. 2021 10 11 1482 1490 10.1002/sctm.21‑0074 34164948
    [Google Scholar]
  131. Kan S. Hariyadi D.M. Grainge C. Knight D.A. Bartlett N.W. Liang M. Airway epithelial-targeted nanoparticles for asthma therapy. Am. J. Physiol. Lung Cell. Mol. Physiol. 2020 318 3 L500 L509 10.1152/ajplung.00237.2019 31913649
    [Google Scholar]
  132. McCarron A. Cmielewski P. Drysdale V. Parsons D. Donnelley M. Effective viral-mediated lung gene therapy: Is airway surface preparation necessary? Gene Ther. 2023 30 6 469 477 10.1038/s41434‑022‑00332‑7 35351979
    [Google Scholar]
  133. Barnes P.J. Oxidative stress in chronic obstructive pulmonary disease. Antioxidants 2022 11 5 965 10.3390/antiox11050965 35624831
    [Google Scholar]
  134. Bisserier M. Sun X.Q. Fazal S. Turnbull I.C. Bonnet S. Hadri L. Novel insights into the therapeutic potential of lung-targeted gene transfer in the most common respiratory diseases. Cells 2022 11 6 984 10.3390/cells11060984 35326434
    [Google Scholar]
  135. Guan Q. Tian Y. Zhang Z. Zhang L. Zhao P. Li J. Identification of potential key genes in the pathogenesis of chronic obstructive pulmonary disease through bioinformatics analysis. Front. Genet. 2021 12 754569 10.3389/fgene.2021.754569 34804123
    [Google Scholar]
  136. Chen Z.H. Kim H.P. Ryter S.W. Choi A.M. Identifying targets for COPD treatment through gene expression analyses. Int. J. Chron. Obstruct. Pulmon. Dis. 2008 3 3 359 370 [PMID: 18990963
    [Google Scholar]
  137. Wang C. Zhou J. Wang J. Progress in the mechanism and targeted drug therapy for COPD. Signal Transduct. Target. Ther. 2020 5 1 248 10.1038/s41392‑020‑00345‑x 33110061
    [Google Scholar]
  138. Eygeris Y. Gupta M. Kim J. Thiophene-based lipids for mRNA delivery to pulmonary and retinal tissues. Proc. Natl. Acad. Sci. USA 2024 121 11 e2307813120 10.1073/pnas.2307813120 38437570
    [Google Scholar]
  139. Kim N. Kwak G. Rodriguez J. Inhaled gene therapy of preclinical muco-obstructive lung diseases by nanoparticles capable of breaching the airway mucus barrier. Thorax 2022 77 8 812 820 10.1136/thoraxjnl‑2020‑215185 34697091
    [Google Scholar]
  140. Hussen B.M. Najmadden Z.B. Abdullah S.R. CRISPR/Cas9 gene editing: A novel strategy for fighting drug resistance in respiratory disorders. Cell Commun. Signal. 2024 22 1 329 10.1186/s12964‑024‑01713‑8 38877530
    [Google Scholar]
  141. Meng M. Li Y. Wang J. Innovative nebulization delivery of lipid nanoparticle-encapsulated siRNA: A therapeutic advance for Staphylococcus aureus-induced pneumonia. J. Transl. Med. 2024 22 1 942 10.1186/s12967‑024‑05711‑9 39407291
    [Google Scholar]
  142. Macrophages R.A.W. Kim M. Jeong H. Zinc oxide nanoparticles suppress LPS-induced NF-κB activation by inducing A20, a negative regulator of NF-κB, in RAW 264.7 macrophages. J. Nanosci. Nanotechnol. 2015 15 6509 6515 10.1166/jnn.2015.10319
    [Google Scholar]
  143. Cortese-Krott M.M. Kulakov L. Opländer C. Kolb-Bachofen V. Kröncke K.D. Suschek C.V. Zinc regulates iNOS-derived nitric oxide formation in endothelial cells. Redox Biol. 2014 2 945 954 10.1016/j.redox.2014.06.011 25180171
    [Google Scholar]
  144. Rahman Sabuj M.Z. Islam N. Inhaled antibiotic-loaded polymeric nanoparticles for the management of lower respiratory tract infections. Nanoscale Adv. 2021 3 14 4005 4018 10.1039/D1NA00205H 36132845
    [Google Scholar]
  145. Agarwal H. Shanmugam V. A review on anti-inflammatory activity of green synthesized zinc oxide nanoparticle: Mechanism-based approach. Bioorg. Chem. 2020 94 103423 10.1016/j.bioorg.2019.103423 31776035
    [Google Scholar]
  146. Ali Zohal M. Yazdi Z. Kazemifar A.M. Daytime sleepiness and quality of sleep in patients with COPD compared to control group. Glob. J. Health Sci. 2013 5 3 150 155 10.5539/gjhs.v5n3p150 23618484
    [Google Scholar]
  147. Choi H.S. Ashitate Y. Lee J.H. Kim S.H. Matsui A. Insin N. Rapid translocation of nanoparticles from the lung airways to the regional lymph nodes. Nat. Biotechnol. 2010 28 12 1300 1303 10.1038/nbt.1696 21057497
    [Google Scholar]
  148. Heo D.N. Yang D.H. Moon H.J. Gold nanoparticles surface-functionalized with paclitaxel drug for treating lung cancer. J. Control. Release 2014 173 1 66 74
    [Google Scholar]
  149. Gao L. Liu X. Zhang Y. Gold nanoparticles as a novel therapeutic agent in treating chronic obstructive pulmonary disease. J. Nanobiotechnology 2021 19 1 10 10.1186/s12951‑020‑06110‑5 33413421
    [Google Scholar]
  150. Khan Y. Arora S. Anti-inflammatory effects of gold nanoparticles in chronic obstructive pulmonary disease: A review. Int. J. Nanomedicine 2020 15 1234 1248 10.2147/IJN.S225745
    [Google Scholar]
  151. Sánchez M. Fernández A. Silver nanoparticles as anti-inflammatory agents in the treatment of respiratory diseases. J. Nanosci. Nanotechnol. 2021 21 4 2336 2346 10.1166/jnn.2021.18547
    [Google Scholar]
  152. Mousa S.A. Samir E. The therapeutic potential of silver nanoparticles in inflammatory lung diseases: Evidence and mechanisms. Nanomedicine 2020 27 102117 10.1016/j.nano.2019.102117
    [Google Scholar]
  153. Gao X. Zhang X. Li M. Role of zinc nanoparticles in modulating inflammation in chronic respiratory diseases: A review. Int. J. Nanomedicine 2020 15 4871 4884 10.2147/IJN.S261911
    [Google Scholar]
  154. Fang J. Zhang Y. Polymeric nanoparticles for targeted drug delivery in chronic obstructive pulmonary disease: Recent advances and future directions. J. Control. Release 2022 339 166 182 10.1016/j.jconrel.2021.09.014
    [Google Scholar]
  155. Liu X. Advances in polymeric nanoparticles for drug delivery in respiratory diseases. Adv. Drug Deliv. Rev. 2023 182 114085 10.1016/j.addr.2022.114085
    [Google Scholar]
  156. Huang Y. Cerium oxide nanoparticles as antioxidants and their therapeutic applications in chronic obstructive pulmonary disease. J. Nanosci. Nanotechnol. 2021 21 8 4554 4563 10.1166/jnn.2021.19234
    [Google Scholar]
  157. Rao C.N.R. Muller A. Carbon nanomaterials: Anti-inflammatory properties and therapeutic potential in chronic obstructive pulmonary disease. Adv. Funct. Mater. 2022 32 11 2109741 10.1002/adfm.202109741
    [Google Scholar]
  158. Tsai C.Y. Shiau A.L. Chen S.Y. Amelioration of collagen-induced arthritis in rats by nanogold. Arthritis Rheum. 2012 64 10 3144 3153 [PMID: 17265489
    [Google Scholar]
  159. Sumbayev V.V. Yasinska I.M. Garcia C.P. Gold nanoparticles downregulate interleukin-1β-induced pro-inflammatory responses. Small 2013 9 3 472 477 10.1002/smll.201201528 23112137
    [Google Scholar]
  160. Rashid M.U. Bhuiyan M.K.H. Quayum M.E. Synthesis of silver nano particles (Ag-NPs) and their uses for quantitative analysis of vitamin C tablets. Dhaka Univ J Pharm Sci 2013 12 1 29 33 10.3329/dujps.v12i1.16297
    [Google Scholar]
  161. Aparna Mani K.M. Vasanthi C. David D.C. Enhanced anti inflammatory activity of phyto-stabilized silver nanoparticles on carrageenan induced paw edema in rats. Int J Pharm Bio Sci 2015 6 575 581
    [Google Scholar]
  162. Ilves M. Palomäki J. Vippola M. Topically applied ZnO nanoparticles suppress allergen induced skin inflammation but induce vigorous IgE production in the atopic dermatitis mouse model. Part. Fibre Toxicol. 2014 11 1 38 10.1186/s12989‑014‑0038‑4 25123235
    [Google Scholar]
  163. Nagajyothi P.C. Cha S.J. Yang I.J. Sreekanth T.V.M. Kim K.J. Shin H.M. Antioxidant and anti-inflammatory activities of zinc oxide nanoparticles synthesized using Polygala tenuifolia root extract. J. Photochem. Photobiol. B 2015 146 10 17 10.1016/j.jphotobiol.2015.02.008 25777265
    [Google Scholar]
  164. Cheng G. Guo W. Han L. Cerium oxide nanoparticles induce cytotoxicity in human lung adenocarcinoma cells via oxidative stress and p53 activation. Int. J. Oncol. 2013 42 5 1692 1700 [PMID: 23467667
    [Google Scholar]
  165. Rehman M.U. Yoshihisa Y. Miyamoto Y. Shimizu T. The anti-inflammatory effects of platinum nanoparticles on the lipopolysaccharide-induced inflammatory response in RAW 264.7 macrophages. Inflamm. Res. 2012 61 11 1177 1185 10.1007/s00011‑012‑0512‑0 22752115
    [Google Scholar]
  166. Rajeshkumar S. Rinitha G. Nanostructural characterization of antimicrobial and antioxidant copper nanoparticles synthesized using novel Persea americana seeds. OpenNano 2018 3 18 27 10.1016/j.onano.2018.03.001
    [Google Scholar]
  167. Chalmers J.D. van Ingen J. van der Laan R. Herrmann J.L. Liposomal drug delivery to manage nontuberculous mycobacterial pulmonary disease and other chronic lung infections. Eur. Respir. Rev. 2021 30 161 210010 10.1183/16000617.0010‑2021 34289985
    [Google Scholar]
  168. Jessamine V. Mehndiratta S. De Rubis G. The] application of nanoparticles as advanced drug delivery] systems in Attenuating COPD. Heliyon 2024 10 3 e25393 10.1016/j.heliyon.2024.e25393 38356590
    [Google Scholar]
  169. Mehta P.P. Dhapte-Pawar V. Inhalable prodrugs for pulmonary therapeutics. Pulmonary Drug Delivery Systems: Material and] Technological Advances. Mehta P.P. Dhapte-Pawar V. Singapore Springer 2023 399 437 10.1007/978‑981‑99‑1923‑9_13
    [Google Scholar]
  170. Mehta P. Kadam S. Pawar A. Bothiraja C. Dendrimers for pulmonary delivery: Current perspectives and future challenges. New J. Chem. 2019 43 22 8396 8409 10.1039/C9NJ01591D
    [Google Scholar]
  171. Uskoković V. Lessons from the history of inorganic nanoparticles for inhalable diagnostics and therapeutics. Adv. Colloid Interface Sci. 2023 315 102903 10.1016/j.cis.2023.102903 37084546
    [Google Scholar]
  172. Plasschaert L.W. MacDonald K.D. Moffit J.S. Current landscape of cystic fibrosis gene therapy. Front. Pharmacol. 2024 15 1476331 10.3389/fphar.2024.1476331 39439894
    [Google Scholar]
  173. Xu X. Huang H. Yin X. Fang H. Shen X. Effect of] lentivirus-mediated CFTR overexpression on oxidative stress injury and inflammatory response in the lung tissue of COPD mouse model. Biosci. Rep. 2020 40 1 BSR20193667 10.1042/BSR20193667 31894837
    [Google Scholar]
  174. Liu J. Han X. Zhang T. Tian K. Li Z. Luo F. Reactive oxygen species (ROS) scavenging biomaterials for anti-inflammatory diseases: From mechanism to therapy. J. Hematol. Oncol. 2023 16 1 116 10.1186/s13045‑023‑01512‑7 38037103
    [Google Scholar]
  175. Xuan L. Ju Z. Skonieczna M. Zhou P.K. Huang R. Nanoparticles‐induced potential toxicity on human health: Applications, toxicity mechanisms, and evaluation models. MedComm 2020 4 4 e327 10.1002/mco2.327
    [Google Scholar]
  176. Kyriakides T.R. Raj A. Tseng T.H. Biocompatibility of nanomaterials and their immunological properties. Biomed. Mat 2021 16 042005 10.1088/1748‑605X/abe5fa
    [Google Scholar]
  177. Guo Y. Bera H. Shi C. Zhang L. Cun D. Yang M. Pharmaceutical strategies to extend pulmonary exposure of inhaled medicines. Acta Pharm. Sin. B 2021 11 8 2565 2584 10.1016/j.apsb.2021.05.015 34522598
    [Google Scholar]
  178. Desai N. Challenges in development of nanoparticle-based therapeutics. AAPS J. 2012 14 2 282 295 10.1208/s12248‑012‑9339‑4 22407288
    [Google Scholar]
  179. Hua S. de Matos M.B.C. Metselaar J.M. Storm G. Current trends and challenges in the clinical translation of nanoparticulate nanomedicines: Pathways for translational development and commercialization. Front. Pharmacol. 2018 9 790 10.3389/fphar.2018.00790 30065653
    [Google Scholar]
  180. Đorđević S. Gonzalez M.M. Conejos-Sánchez I. Current hurdles to the translation of nanomedicines from bench to the clinic. Drug Deliv. Transl. Res. 2022 12 3 500 525 10.1007/s13346‑021‑01024‑2 34302274
    [Google Scholar]
  181. Lekkala V.V.V. Reddy M.C. Reddy V.C. Advancements in nanoparticles-based therapies for biomedical applications. Nano-Struct Nano-Objects 2024 40 101365 10.1016/j.nanoso.2024.101365
    [Google Scholar]
  182. Puccetti M. Pariano M. Schoubben A. Giovagnoli S. Ricci M. Biologics, theranostics, and personalized medicine in drug delivery systems. Pharmacol. Res. 2024 201 107086 10.1016/j.phrs.2024.107086 38295917
    [Google Scholar]
  183. Mi P. Stimuli-responsive nanocarriers for drug delivery, tumor imaging, therapy and theranostics. Theranostics 2020 10 10 4557 4588 10.7150/thno.38069 32292515
    [Google Scholar]
  184. Patra J.K. Das G. Fraceto L.F. Nano based drug delivery systems: Recent developments and future prospects. J. Nanobiotechnology 2018 16 1 71 10.1186/s12951‑018‑0392‑8 30231877
    [Google Scholar]
/content/journals/cms/10.2174/0126661454405390251015163802
Loading
Advancements in Nanotechnology for Targeted Drug Delivery in Chronic Obstructive Pulmonary Disease
Bentham Science Publishers ; https://doi.org/10.2174/0126661454405390251015163802
/content/journals/cms/10.2174/0126661454405390251015163802
/content/journals/cms/10.2174/0126661454405390251015163802
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: nanoparticles ; prodrug approach ; liposomes ; gene therapy ; dendrimers ; Chronic obstructive pulmonary disease

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test